These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 9127315

  • 1. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L, Goldman H, Odze RD.
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [Abstract] [Full Text] [Related]

  • 2. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.
    Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M.
    Cancer Res; 1998 Apr 15; 58(8):1730-5. PubMed ID: 9563491
    [Abstract] [Full Text] [Related]

  • 3. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
    Soslow RA, Remotti H, Baergen RN, Altorki NK.
    Mod Pathol; 1999 Mar 15; 12(3):239-50. PubMed ID: 10102608
    [Abstract] [Full Text] [Related]

  • 4. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV.
    Am J Gastroenterol; 2005 Jun 15; 100(6):1257-64. PubMed ID: 15929754
    [Abstract] [Full Text] [Related]

  • 5. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
    von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, Sarbia M.
    Mol Carcinog; 2006 Oct 15; 45(10):786-94. PubMed ID: 16921482
    [Abstract] [Full Text] [Related]

  • 6. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT.
    Cancer; 2007 Feb 15; 109(4):658-67. PubMed ID: 17211865
    [Abstract] [Full Text] [Related]

  • 7. Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma.
    Katori H, Nozawa A, Tsukuda M.
    Acta Otolaryngol; 2007 Nov 15; 127(11):1207-13. PubMed ID: 17851915
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.
    De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG.
    Hepatology; 1998 Oct 15; 28(4):971-9. PubMed ID: 9755233
    [Abstract] [Full Text] [Related]

  • 9. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK.
    Cancer Epidemiol Biomarkers Prev; 2008 Jun 15; 17(6):1380-5. PubMed ID: 18559552
    [Abstract] [Full Text] [Related]

  • 10. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
    Villanacci V, Bellone G, Battaglia E, Rossi E, Carbone A, Prati A, Verna C, Niola P, Morelli A, Grassini M, Bassotti G.
    Hum Pathol; 2008 Mar 15; 39(3):403-9. PubMed ID: 18261624
    [Abstract] [Full Text] [Related]

  • 11. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?
    Millikan KW, Mall JW, Myers JA, Hollinger EF, Doolas A, Saclarides TJ.
    Am Surg; 2000 Apr 15; 66(4):401-5; discussion 405-6. PubMed ID: 10776879
    [Abstract] [Full Text] [Related]

  • 12. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study.
    Whittles CE, Biddlestone LR, Burton A, Barr H, Jankowski JA, Warner PJ, Shepherd NA.
    J Pathol; 1999 Apr 15; 187(5):535-40. PubMed ID: 10398118
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
    Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, Sawyers J, Beauchamp D.
    Mod Pathol; 1998 Sep 15; 11(9):805-13. PubMed ID: 9758359
    [Abstract] [Full Text] [Related]

  • 16. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D, Peters JH, Oh D, Kuramochi H, Shimizu D, Demeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, DeMeester TR, Danenberg P.
    Surgery; 2005 Oct 15; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor expression in Barrett's esophagus.
    Poller DN, Steele RJ, Morrell K.
    Arch Pathol Lab Med; 1992 Nov 15; 116(11):1226-7. PubMed ID: 1444753
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
    Krishnadath KK, Tilanus HW, van Blankenstein M, Bosman FT, Mulder AH.
    J Pathol; 1995 Feb 15; 175(2):175-80. PubMed ID: 7738712
    [Abstract] [Full Text] [Related]

  • 20. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.
    Torres C, Turner JR, Wang HH, Richards W, Sugarbaker D, Shahsafaei A, Odze RD.
    Cancer; 1999 Feb 01; 85(3):520-8. PubMed ID: 10091725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.